Lyra Therapeutics Inc. held its Annual Meeting of Stockholders on May 14, 2025. During the meeting, several proposals were considered and voted upon. The election of two Class II Directors, C. Ann Merrifield and Harlan W. Waksal, M.D., was approved. The ratification of the appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was also approved. Additionally, an amendment to the Company's Restated Certificate of Incorporation to effect a reverse stock split of Common Stock was approved, as well as an adjournment of the meeting if necessary to solicit additional proxies for the reverse stock split proposal.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.